Your browser doesn't support javascript.
loading
Biomarkers in breast cancer: a consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Colomer, R; Aranda-López, I; Albanell, J; García-Caballero, T; Ciruelos, E; López-García, MÁ; Cortés, J; Rojo, F; Martín, M; Palacios-Calvo, J.
Affiliation
  • Colomer, R; Hospital Universitario La Princesa. Departamento de Oncología Médica. Madrid. Spain
  • Aranda-López, I; General University Hospital of Alicante. Pathology Department. Alicante. Spain
  • Albanell, J; Pompeu Fabra University. Mar University Hospital. Medical Oncology Department. Barcelona. Spain
  • García-Caballero, T; University Hospital Complex of Santiago. Pathology Department. Santiago de Compostela. Spain
  • Ciruelos, E; Doce de Octubre University Hospital. Medical Oncology Department. Madrid. Spain
  • López-García, MÁ; Virgen del Rocio University Hospital. Pathology Department. Seville. Spain
  • Cortés, J; Ramón y Cajal University Hospital. Medical Oncology Department. Madrid. Spain
  • Rojo, F; Fundación Jiménez Díaz University Hospital. Pathology Department. Madrid. Spain
  • Martín, M; Gregorio Marañón University Hospital. Medical Oncology Department. Madrid. Spain
  • Palacios-Calvo, J; Ramón y Cajal University Hospital. Pathology Department. Madrid. Spain
Clin. transl. oncol. (Print) ; Clin. transl. oncol. (Print);20(7): 815-826, jul. 2018. tab, graf
Article in En | IBECS | ID: ibc-173633
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. This expert group recommends determining in all cases of breast cancer the histologic grade and the alpha-estrogen receptor (ER), progesterone receptor, Ki-67 and HER2 status, in order to assist prognosis and establish therapeutic options, including hormone therapy, chemotherapy and anti-HER2 therapy. One of the four available genetic prognostic platforms (MammaPrint®, Oncotype DX®, Prosigna® or EndoPredict®) may be used in node-negative ER-positive patients to establish a prognostic category and decide with the patient whether adjuvant treatment may be limited to hormonal therapy. Newer technologies including next-generation sequencing, liquid biopsy, tumour-infiltrating lymphocytes or PD-1 determination are at this point investigational
RESUMEN
No disponible
Subject(s)
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Breast Neoplasms / Gene Expression Profiling Type of study: Guideline / Prognostic_studies Limits: Female / Humans Language: En Journal: Clin. transl. oncol. (Print) Year: 2018 Document type: Article
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Breast Neoplasms / Gene Expression Profiling Type of study: Guideline / Prognostic_studies Limits: Female / Humans Language: En Journal: Clin. transl. oncol. (Print) Year: 2018 Document type: Article